Replaces Prod. #: BML-CN222
A potent and selective, cell-permeable inhibitor of nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC). Inhibition is irreversible. Inhibits also the basal, the YC-1 and the coenhanced sGC activity. Complete inhibition of NO-induced relaxation in vascular and nonvascular smooth muscle at 1μM.
Product Specification
| Alternative Name: | 4H-8-Bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one |
| |
| Formula: | C9H5BrN2O3 |
| |
| MW: | 269.1 |
| |
| CAS: | 204326-43-2 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White to off-white crystalline powder. |
| |
| Solubility: | Soluble in DMSO or 100% ethanol; insoluble in water. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from moisture. |
| |
Please mouse over
Product Literature References
Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxide synthase: I. Fleming, et al.; PNAS
96, 1123 (1999),
Abstract;
Vascular smooth muscle contraction is an independent regulator of endothelial nitric oxide production: L. Bang, et al.; Scand. Cardiovasc. J.
33, 33 (1999),
Abstract;
Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase: S.P. Olesen, et al.; Br. J. Pharmacol.
123, 299 (1998),
Abstract;
